Patents by Inventor Benjamin P. Vokits

Benjamin P. Vokits has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SPIROHEPTANYL HYDANTOINS AS ROCK INHIBITORS
    Publication number: 20240092755
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: August 16, 2022
    Publication date: March 21, 2024
    Inventors: Benjamin P. Vokits, Scott A. Shaw
  • Spiroheptanyl hydantoins as rock inhibitors
    Patent number: 11447487
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: September 20, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Benjamin P. Vokits, Scott A. Shaw
  • Triazolopyridine inhibitors of myeloperoxidase
    Patent number: 11059818
    Abstract: The present invention provides compounds of Formula (I). wherein A and Z are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: July 13, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joanne M. Smallheer, Carol Hui Hu, Meriah Neissel Valente, Scott A. Shaw, Benjamin P. Vokits, Oz Scott Halpern
  • SPIROHEPTANYL HYDANTOINS AS ROCK INHIBITORS
    Publication number: 20210155618
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
    Type: Application
    Filed: July 11, 2018
    Publication date: May 27, 2021
    Inventors: Benjamin P. Vokits, Scott A. Shaw
  • Triazolopyridine inhibitors of myeloperoxidase and/or EPX
    Patent number: 11008317
    Abstract: The present invention provides compounds of Formula (I); wherein the substituents are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: May 18, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ellen K. Kick, Joanne M. Smallheer, Scott A. Shaw, Benjamin P. Vokits, Andrew K. Dilger, Charles G. Clark, Meriah Neissel Valente, Sutjano Jusuf, Nicholas R. Wurtz
  • TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE
    Publication number: 20200291015
    Abstract: The present invention provides compounds of Formula (I). wherein A and Z are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and may be useful for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Application
    Filed: March 10, 2017
    Publication date: September 17, 2020
    Inventors: Joanne M. Smallheer, Carol Hui HU, Meriah Neissel Valente, Scott A. Shaw, Benjamin P. Vokits, Oz Scott Halpern
  • Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase
    Patent number: 9920075
    Abstract: The present invention provides compounds of Formula (I): wherein A and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: March 20, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Nicholas R. Wurtz, Andrew Quoc Viet, Scott A. Shaw, Benjamin P. Vokits, Ellen K. Kick, Meriah Neissel Valente, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty, Sutjano Jusuf
  • TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE
    Publication number: 20170247396
    Abstract: The present invention provides compounds of Formula (I): wherein A and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.
    Type: Application
    Filed: September 9, 2015
    Publication date: August 31, 2017
    Inventors: Nicholas R. Wurtz, Andrew Quoc Viet, Scott A. Shaw, Benjamin P. Vokits, Ellen K. Kick, Meriah Neissel Valente, Andrew K. Dilger, Kumar Balashanmuga Pabbisetty, Sutjano Jusuf